← Eichor
Condition: Lung Adenocarcinoma Stage Iii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lung Adenocarcinoma Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
Phase 3 · 1 location(s) · Sun Yat-Sen University Cancer Center · NCT07058428Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carbo
Phase 2 · 34 location(s) · National Cancer Institute (NCI) · NCT05198830Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
Phase 3 · 1 location(s) · Fudan University · NCT06031246Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Secti
Phase 3 · 1 location(s) · Fudan University · NCT06031181AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06943820Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients Wi
Phase 3 · 1 location(s) · Institut Bergonié · NCT04339218A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durval
Phase 1 · 19 location(s) · AstraZeneca · NCT07391670Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
Phase 3 · 3 location(s) · Sun Yat-sen University · NCT07481786Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Phase 3 · 1 location(s) · Fudan University · NCT05717803Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3 · 15 location(s) · Maia Biotechnology · NCT06908304Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Segmentectomy for Solid-dominant Lung Cancer
Phase 3 · 1 location(s) · Fudan University · NCT06634966Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Phase N/A · 745 location(s) · Alliance for Clinical Trials in Oncology · NCT05334069Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung
Phase 2 · 3 location(s) · Emory University · NCT06495125Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT07314216Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Phase 2/Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03755739Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.